Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation - Quiz - MDSpire

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation

  • By

  • Caroline Foxton

  • Bradley Waldron

  • Alexander Wurzer

  • Calogero D’Alessandria

  • Alfred Morgenstern

  • Frank Bruchertseifer

  • Tea Kirkegaard Nielsen

  • Rikke Veggerby Grønlund

  • Mathias Wikke Hallund

  • Daniel J. Stevens

  • July 16, 2026

Share

Original Source(s)

Actinium-225-rhPSMA-10.1 as a novel, alpha-particle-emitting therapy for prostate cancer: results of a preclinical evaluation

  • by Caroline Foxton, Bradley Waldron, Alexander Wurzer, Calogero D’Alessandria, Alfred Morgenstern, Frank Bruchertseifer, Tea Kirkegaard Nielsen, Rikke Veggerby Grønlund, Mathias Wikke Hallund, Daniel J. Stevens

  • July 16, 2026

Related Content

Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis

Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies

Spinal metastases in geriatric patients: a retrospective single-center comparison of mortality and surgical outcomes following neurosurgical treatment